Summary
This Form 8-K filing from Vertex Pharmaceuticals (VRTX) on March 17, 2005, details changes to the compensation structure for its non-employee directors, effective March 14, 2005. The adjustments aim to ensure competitive compensation to attract and retain qualified individuals, acknowledging an increased workload. Key changes include a new annual retainer, meeting fees, and committee chair retainers, alongside equity awards in the form of stock options for new and existing directors.
Key Highlights
- 1Vertex Pharmaceuticals is updating its compensation for non-employee directors to remain competitive and address increased responsibilities.
- 2Effective March 14, 2005, new cash compensation includes an annual retainer of $25,000 for board service.
- 3Additional cash compensation is provided for attending Board and committee meetings, with varying rates for in-person and conference call meetings.
- 4Committee Chairs will receive additional annual retainers: $20,000 for Corporate Governance & Nominating, $15,000 for Audit, and $10,000 for Management Development & Compensation.
- 5New non-employee directors will receive an initial grant of 20,000 stock options vesting over four years.
- 6Existing non-employee directors receive an annual grant of 10,000 stock options, exercisable immediately, on June 1st of each year.